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Abstract
Background—Cervical cancer is the most common cancer in women in low-income countries.
Although cervical cancer incidence and mortality is higher in HIV-positive women, resource
limitations restrict the implementation of systematic screening programs in these women. We
explored the potential for targeted screening by assessing the prevalence, severity and predictors
of cervical squamous intra-epithelial lesions (SILs) in HIV-positive women in Cameroon.
Methods and findings—We conducted a cross-sectional study of women on antiretroviral
therapy in Cameroon. Socio-demographic, behavioral, and clinical information was obtained from
eligible women. Cervical exfoliated cells were then collected, a conventional cytology performed
and epithelial lesions classified according to the Bethesda 2001 system.
A total of 282 women, aged 19 to 68 years, were enrolled in this study. The median CD4 count
was 179 cells/microliter (interquartile range: 100 to 271). SILs were detected in 43.5% of the 276
women with satisfactory samples: including atypical squamous cells of unknown significance
(ASCUS) 0.7%, low-grade SIL (LSIL) 25.0%, atypical squamous cells, cannot exclude high grade
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lesions (ASC-H) 14.5%, and high-grade SIL (HSIL) 3.3%. None of the demographic or clinical
characteristics considered significantly predicted the presence of any SILs or the presence of
severe lesions requiring colposcopy.
Conclusion—The prevalence of SIL in women on antiretroviral therapy in Cameroon was high
underscoring the need for screening and care in this population. In the absence of any accurate
demographic or clinical predictor of SIL, targeted screening does not seem feasible. Alternative
affordable screening options need to be explored.
Keywords
Cervical neoplasm; HIV; Screening; Cameroon; Epidemiology
INTRODUCTION
Cervical cancer is the most common cancer in women in low-income countries[1].
Compared to immuno-competent women, HIV-positive women have a higher prevalence,
incidence and progression rate of precancerous cervical lesions[2,3]. Enhancing early
detection and treatment of precancerous lesions through screening could reduce the burden
of cervical cancer in these HIV-positive women[4].
Despite the relatively high risk of precancerous and cancerous cervical lesions in HIV-
positive women, unlike many other opportunistic infections, the current management of
women initiating antiretroviral therapy (HAART) in most low-income countries does not
include a systematic screen for cervical cancer or precancerous lesions. Targeted screening
among HIV-positive women could potentially increase the cost-effectiveness of screening in
these resource-limited settings by increasing the ratio of the number of cases detected per
screening test. However, for targeted screening to be effective socio-demographic and
clinical factors associated with a higher prevalence and severity of lesions need to be
identified.
In this paper, we describe the prevalence and severity of cervical epithelial lesions in women
initiating HAART in Cameroon and assess the clinical predictors of lesions in these women.




This study was approved by the Cameroon National Ethics Committee and the University of
North Carolina at Chapel Hill’s Biomedical IRB. All participants provided written informed
consent prior to inclusion in the study.
Study design and study population
We conducted a cross-sectional study of HIV-positive women recruited from three HIV-care
clinics in Cameroon: the Bamenda Provincial Hospital AIDS Treatment Center (ATC), the
Limbe Provincial Hospital ATC and the Nylon District Hospital ATC in Douala. The clinics
are all located in urban areas in Cameroon but provide regular care to patients from
surrounding urban and peripheral rural areas. Consecutive HIV-positive women receiving
care in these clinics, between August and September 2008, were invited to participate in the
study. Women aged 18 years or more, who initiated HAART within a year preceding study
enrollment and consented to study procedures, were eligible. Women who were either
pregnant, having menses or had a previous total hysterectomy were excluded.
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Three research assistants with previous medical training were trained on study procedures
and cervical sampling to optimize the quality of cervical smears. After providing usual care,
clinicians at each site referred the patients to our research assistants who then explained the
study to each eligible patient. After obtaining written informed consent and verifying
eligibility, data on demographic and clinical characteristics was collected with the aid of a
standardized questionnaire. The assistants then collected cervical smear samples using
conventional methods. Two slides were made for each participant. The slides were
immediately fixed using a 95% ethanol solution and stored at room temperature for the
duration of patient enrollment. These slides were sent for analysis and storage in the
laboratory of the Center for the Study and Control of Communicable Disease (CSCCD) of
the Faculty of Medicine and Biomedical Sciences, Yaoundé, Cameroon.
Slides were stained by the Papanicolau’s method and examined under the microscope by a
trained cytologist. Each slide was scored according to the Bethesda 2001 system as
unsatisfactory, negative, atypical squamous cells of uncertain significance (ASCUS), low-
grade squamous intraepithelial lesions (LSIL), atypical squamous cells, cannot exclude high
grade lesions (ASC-H), high-grade SIL (HSIL), or invasive cervical cancer[5]. Cytology
readings were conducted blinded of clinical characteristics. For quality control purposes,
both research assistants and cytologists received specific training related to the study, two
slides were made and analyzed for each patient (the most severe result was considered the
final result, in case of differences between both slides), and slides with lesions were double-
checked by a cytologist external to the study (differences were resolved by consensus).
Furthermore, a subset of 25 slides were reviewed by an experienced cytologist at the
University of North Carolina at Chapel Hill – the percentage agreement on the presence of
lesions or not was 76%, (kappa=0.49) while the percentage agreement on lesions being
ASC-H/HSIL or not was 60%(kappa=0.26). The potential impact of these limitations with
conventional cytology was assessed in sensitivity (bias) analyses[6].
Statistical analysis
Data collected were entered into MS Access interface on Epi-info 2000. Statistical analyses
were conducted using SAS version 9.2 (SAS institute inc, Cary NC) and STATA version 10
(STATA corps, Texas USA). Two outcomes, based on cervical cytology, were considered:
1) Prevalent cervical lesions (defined as the presence of any cervical epithelial lesions); 2)
Prevalent ASC-H/HSIL (lesions requiring colposcopy). Participant’s age, marital status,
parity, number of lifetime sex partners, age at first sexual intercourse, history of hormonal
contraception, history of exposure to cigarette smoke, CD4 count, and AIDS clinical stage
were considered as potential clinical predictors of lesions. These characteristics were chosen
based on the ease with which they can be elicited and recorded in a clinical setting and
previous literature describing their association with the presence of cervical lesions or a
plausible etiological role.
All predictors considered were included in multivariable analyses. For each outcome, an
initial (full) model that includes all the predictors was created. We then attempted to
determine a reduced model based on a parsimonious subset of clinically and statistically
significant predictors identified by a stepwise backward elimination strategy[7]. A final
reduced model was thus obtained retaining only predictors that when dropped resulted in a
likelihood ratio test p-value<0.2 or a more than 10% change in the area under the curve of
the ROC plot (c-statistic). A reduced model was possible only for the prediction of prevalent
SIL (and not for the prediction of ASC-H/HSIL).
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The models developed were based on the full sample. However the internal validity of the
models’ performance was ascertained by implementing the models to three subsets of the
sample corresponding to each study site. The c-statistics for the models were all within 20%
of the model implemented on the full sample.
One objective of this analysis was to identify if any clinical predictor(s) could be used in a
resource-limited settings to develop a targeted screening approach. We thus developed and
assessed potential risk scores for targeting screening only to patients more likely to have
lesions. Risk scores were developed from each of the three final models: the two models for
predicting the presence of any lesion (the full model and the reduced model) and the full
model for predicting the presence of ASC-H/HSIL. The numeric score assigned to each
predictor was based on the model slope coefficients. To allow for a simple and feasible
application in clinical settings, each predictor score was obtained by multiplying the model
slope coefficients by 10 and then rounding to the lower integer. The aggregate risk score
was based on the sum total of each predictor score. We assessed the performance
(sensitivity, specificity, positive and negative predictive values) of each risk score for
targeting 25%, 50% and 75% of women. We also evaluated the total errors that would result
from implementing either targeted screening based on the risk scores versus universal or no
screening. Total unweighted errors were estimated as the sum of ‘false negative’ and ‘false
positive’ errors, respectively defined as the number of patients with no lesion being screened
and the number of patients with lesions not being screened. Total weighted errors were also
estimated taking into account the relative cost (both monetary and non-monetary) associated
with having a ‘false negative’ versus a ‘false positive’ error.
RESULTS
Study population
Altogether 282 women were enrolled in this study. Participants’ age ranged from 19 to 68
years, with a mean of 36 years. Most participants (73.4%) were from urban areas (Table 1).
As many as 26.9% were widowed, while 21.3% had never been married. The median parity
was 2 (range 0–11). Active tobacco exposure (2.5%) and oral contraceptive pill usage
(23.8%) was relatively infrequent. The number of lifetime partners exceeded 5 in 25.2% of
participants. A history of genital warts was reported by 7.1% of participants while 43.3%
could not say if they previously had genital warts or not.
HIV diagnosis had preceded study enrolment by 18.5 months on average (range 0–136
months). The median CD4 count was 179 cells/microliter (interquartile range: 100 to 271).
The vast majority of patients (80.9%) had advanced HIV disease (WHO HIV clinical stages
III/IV). Only 2.1% were certain they had previously had a Pap smear.
Prevalence and severity of lesions
The prevalence of SIL was 43.5% (95%CI: 37.5, 49.6%) in the 276 women with satisfactory
samples. The prevalence of specific abnormalities was ASCUS 0.7% (95%CI: 0.09, 2.3%),
LSIL 25.0% (95%CI: 20.0, 30.5%), ASC-H 14.5% (95%CI: 10.6, 19.2%), and HSIL 3.3%
(95%CI: 1.5, 6.1%). The overall prevalence of ASC-H/HSIL was 17.8% (95% CI: 13.4,
22.8%).
Association of clinical predictors and prevalent SIL
Most of the clinical factors assessed were either weakly associated with prevalent SIL or had
a poor precision and were statistically insignificant (Table 2). Compared to women from
urban areas, SIL tended to be more frequent in women from rural areas (adjusted OR: 1.68;
95%CI: 0.88, 3.18). SIL tended to be more frequent in women aged 26–59 compared to all
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other women (aOR: 1.57; 0.65, 3.81). Although estimates were relatively imprecise, the
odds of SIL tended to be lower in women with HIV stage III/IV compared to women in
stage I/II (aOR: 0.63; 95%CI: 032, 1.23). The odds of SIL did not differ substantially by
marital status, educational status, previous exposure to tobacco smoke, previous pill usage,
parity, age at first sex, time since HIV diagnosis or CD4 count (all aORs were more than 0.8
and less than 1.25).
The overall predictive value of the model with all these variables was relatively low with a
c-statistic of 0.60. A reduced model included only two predictors: participants’ residence
(rural vs. urban aOR 1.58 (95% CI: 0.87, 2.87) and HIV clinical stage (HIV stage III/IV vs.
I/II aOR 0.61 (95% CI: 0.31, 1.19)), with a c-statistic of 0.58.
Association of clinical predictors and lesions requiring colposcopy/biopsy
Bivariable and multivariable associations with ASC-H/HSIL were relatively weak (Table 2).
Although not statistically significant, ASC-H/HSIL tended to be more frequent in women
who reported age at first sexual intercourse less than 16 years (aOR: 1.27; 95%CI: 0.64,
2.53) as well as in patients with CD4 counts below 200 (aOR: 1.49; 95%CI: 0.72, 3.07).
ASC-H/HSIL tended to be less frequent in women self-reporting exposure to tobacco smoke
(aOR: 0.66, 95%CI: 0.33, 1.34). The odds of ASC-H/HSIL did not differ substantially by
age, marital status, education, residence, age, previous pill usage, parity, HIV clinical stage,
or time since HIV diagnosis (all aORs were more than 0.8 and less than 1.25). With a c-
statistic of 0.59, the overall predictive value of the model with all these variables was also
low.
Assessment of clinical risk scores for targeted screening
The clinical risk scores developed are defined and assessed in Tables 3 and 4. Overall the
classification accuracy based on these scores were all less than 70%. If the risk score based
on the full model for any SIL was used to target the screening of 25% of women, then only
35.7% of women with lesions would have been screened while 23% of women with no
lesions would be screened as well. If the target was to screen 25% of women with ASC-H/
HSIL, then using the score based on the full model predicting ASC-H/HSIL would result in
38.1% of women with ASC-H/HSIL lesions being screened while 26.7% of women with no
ASC-H/HSIL would also be screened.
It is worth noting that despite the relatively poor performance of these scores, their value
compared to universal screening or no screening was a function of the relative weight given
to ‘false negative’ errors compared to ‘false positive’ errors. In screening for any lesion,
when ‘false negative’ errors were considered equal to ‘false positive’ errors, then the total
error rates associated with targeting 50% (406 errors per 1000 women) or 25% (410 errors
per 1000 women) of women was lower than each of universal screening (565 errors per
1000 women) or no screening (435 errors per 1000 women). However, as the relative cost of
‘false negative’ errors (compared to ‘false positive’ errors) increased, universal screening
tended towards having the least total errors while the total errors associated with screening
fewer proportions of patients increased (Figure 1). Similar trends were observed in assessing
potential screening for ASC-H/HSIL only (Figure 2). While no screening was associated
with the least errors when ‘false negative’ errors were considered equal to ‘false positive’
errors, increasing the proportion of women screened was a preferable option when the
former errors were at least five times the latter.
Bias analyses
We conducted bias analyses assessing what the true population prevalence of lesions could
be considering the inaccuracies in conventional cytology. Our analysis showed that a lower
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sensitivity of cytology would mean that the study tended to underestimate the true
prevalence while a lower specificity would have resulted in the study overestimating the true
prevalence. Our data were compatible with a true population prevalence of lesions ranging
from 19.3% (when the sensitivity was 100% and the specificity 70%) to 87.0% (when the
sensitivity was 50% and specificity 100%). Meanwhile the prevalence of ASC-H/HSIL
could be as low as 0% (if the specificity was 80% or less) and as high as 35.6% (when
sensitivity was 50% and specificity 100%).
DISCUSSION
To appraise the need and potential for targeted screening for cervical cancer in HIV-positive
women in resource-limited settings, we assessed the prevalence, severity and predictors of
SIL in women initiating antiretroviral therapy in Cameroon. We document that the
prevalence of precancerous lesions is high in these women. Approximately twenty percent
of these women have lesions severe enough to warrant colposcopy. In this study population,
readily available demographic and clinical factors, both individually and as a group, did not
accurately distinguish women with lesions from those without.
While the overall prevalence of any cervical lesion in this population appears high (43%), it
is within the range described in women in similar conditions. Among HIV-positive pregnant
women in Yaounde, Cameroon, lesions were detected in 40%, including 12% with high
grade lesions[8]. The prevalence of SIL in HIV-seropositive women living in sub-Saharan
Africa has ranged from 15 to 48% in Burkina Faso[9], Kenya[10], South Africa[11,12],
Zimbabwe[13], Rwanda[14], Malawi[15] and Cote d’Ivoire[16]. The highest prevalence of
SIL (76%) so far was detected in a study of 150 HIV-positive women in Zambia who had a
median CD4 count of 165/uL[17]. Although an unusually low prevalence of 7% was
reported in a study of 691 women in Tanzania, the vast majority (86%) of these women were
in WHO clinical stage I and only 12% had CD4 count less than 200[18].
The prevalence in our study could be influenced by study population characteristics or the
accuracy of cytology results. Though we sampled in three different clinics, the sample may
not have been exactly representative of all HIV-positive women in Cameroon as the clinics
were conveniently selected and not randomly chosen. We do not however expect the
difference to be substantial as the clinics sampled offer care to a very high number of
patients in regions with the highest HIV-prevalences and our participant characteristics were
similar to those reported nationwide[19]. Potential errors due to the Pap smear’s low
sensitivity could actually mean that our prevalence is an underestimate. Nevertheless, the
sensitivity of cytology in this study was assured by research assistants being trained to
insure adequate sample collection, collecting two slides per patient to reduce sampling error
and having the interpretations validated by an experienced cytologist. The latter review
suggested a tendency of the initial cytologist to over classify participants as having lesions.
Our bias analyses however shows that the lowest true population prevalence of lesions
compatible with our data was in the order of 19% which is still relatively high.
The high prevalence of cervical lesions in this population reiterates the current need to offer
screening and care for cervical precancerous lesions in HIV-positive women. Despite being
at increased risk for cervical cancer, less than 5% of participants in our study had previously
been screened. Access to antiretrovirals has dramatically increased in developing countries.
While the increased survival that is expected to accompany this increased access the effect
on cervical precancerous lesions is expected to be moderate at best, as HAART has a very
limited effect, if any, on HPV persistence and the progression of lesions[20]. Even while on
antiretrovirals women will still need to be screened or receive other preventive care for
cervical cancer.
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We are not aware of any other study that assessed the potential for clinical risk scores for
targeted cervical cancer screening in HIV-positive women. Because most studies were
conducted to establish the association between HIV infection and the presence of SIL, very
few assessed the risk factors specific to HIV-positive women. Amongst the few that did,
immunosuppression (low CD4 count), high HIV viral load and or infection with high-risk
HPV types tended to be associated with the presence of SIL[10, 14, 16, 17]. While our
sample size was adequate for estimating prevalence, only a limited number of covariates
could be considered as potential predictors. Predictors were thus judiciously chosen taking
into account the established literature and the ease of clinical assessment. Women with
lower CD4 counts and younger age at first sex thus appeared more likely to have severe
lesions. We did not consider HIV viral load as resource limitations render it difficult to
ascertain in most patients, making it of little clinical use in this setting. Unexpectedly,
women who self-reported exposure to cigarette smoke or a history of taking contraceptive
pills tended to be less likely to have lesions. We attribute these apparent lower odds to these
factors being indicators of higher socioeconomic status in these settings. It is not clear why
women with more advanced clinical HIV disease appeared less likely to have lesions.
Nevertheless this association was relatively imprecise.
Considered as a group, the clinical predictors only slightly performed better than chance in
differentiating women who had lesions (or women with severe lesions) from those without.
For comparison the commonly used Framingham cardiovascular risk score had a c-statistic
in the order of 0.65 –0.70 in a population of diabetics in the UK[21]. Nonetheless, the choice
between universal screening, targeted screening or no screening would depend on how much
policy makers value the cost of ‘false negative’ errors relative to the cost of ‘false positive’
errors. We expect that most would attribute a higher long-term cost to ‘false negative’ errors
than to ‘false positive’ errors as cancer can develop in the former, while the latter would
only result in an unnecessary pap smear. With this being the case, strategies advocating for
more screening (thus with higher sensitivity and lower ‘false negatives’) will tend to be
better options. Formal cost-effectiveness analyses may aid in further clarifying which option
is best in each setting.
In addition to prevalence, the need to screen would also depend on the progression of lesions
towards self-resolution or cancer. It was not possible to assess the progression or regression
of lesions, given the cross-sectional nature of our study. Further studies would need to assess
the long-term progression of lesions in HIV-positive women in this setting.
In conclusion, the prevalence of SIL in women initiating antiretroviral therapy in Cameroon
was high. This high prevalence, in light of the potential to treat precancerous lesions when
detected early and the limited role of HAART on the progression of lesions, underscores the
need for screening in this population. Targeted screening for SIL using clinical and
demographic predictors among HIV positive women did not appear feasible. In the absence
of any accurate demographic or clinical predictor of SIL, alternative affordable screening
options need to be explored. A prospective study of the long-term evolution of these lesions
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Total weighted errors associated with screening for any precancerous lesion by the relative
‘cost’ of ‘false negative’ errors compared to ‘false positive’ errors. (A–C: Screening based
on risk score with a cut-off targeting 25%, 50% and 75% of women for A, B and C
respectively; D: Universal screening; E: No screening). Note that ‘cost’ is used as a generic
term, not just limited to monetary value, while ‘false positive’ and ‘false negative’
respectively refer to screening a patient with no lesion and not screening a patient with
lesions.
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Total weighted errors associated with screening for ASC-H/HSIL by the relative ‘cost’ of
‘false negative’ errors compared to ‘false positive’ errors. (A–C: Screening based on risk
score with a cut-off targeting 25%, 50% and 75% of women for A, B and C respectively; D:
Universal screening; E: No screening). Note that ‘cost’ is used as a generic term, not just
limited to monetary value, while ‘false positive’ and ‘false negative’ respectively refer to
screening a patient with no severe lesion and not screening a patient with severe lesions.
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Table 1
Socio-demographic and clinical characteristics in 282 women initiating HAART in Cameroon
Characteristic Level N %
Marital status Never married 60 21.3
Married monogamous 56 19.9
Married polygamous 13 4.6








Residence Urban 207 73.4
Rural 75 26.6
Previous use of hormonal pills Yes 67 23.8
No 215 76.2








Previous Pap smear No 269 95.4
Yes 6 2.1
Don’t know/missing 7 2.5







Sex partners since HIV diagnosis 0 127 45.0
1 136 48.2
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Characteristic Level N %
2+ 19 6.8
Lifetime condom use Never 102 36.2
Less than 50% of the time 138 48.9
More than 50% of the time 39 13.8
Always 3 1.1
Condom use since HIV diagnosis Never 29 10.3
Less than 50% of the time 37 13.1
More than 50% of the time 19 6.7
Always 69 24.5
No new partner/missing 128 45.4
History of genital warts No 140 49.6
Yes 20 7.1
Don’t Know/missing 122 43.3
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Table 3
Definition of clinical risk scores developed and assessed for predicting the prevalence of cervical precancerous
lesions in women initiating HAART in Cameroon
Characteristic Score
Full model for predicting prevalent SIL
HIV diagnosed within 1 year 2
Age at first sex less than or equal 16 years 2
Not exposed to tobacco 2
Secondary/tertiary education 2
Rural residence 5
WHO HIV Stage I/II 5
Age 26–59 years 5
TOTAL 23




No previous use of pills 2
Age at first sex less than or equal 16 years 3
Not-exposed to tobacco 4
CD4 count less than 200 4
TOTAL 17
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